Tag: encorafenib FDA approval

Home / encorafenib FDA approval

Categories

Encorafenib with cetuximab and mFOLFOX6 is approved by the USFDA for metastatic colorectal cancer with a BRAF V600E mutation

On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
encorafenib-fda-approval

Scan the code